Two clinical trials show safety of stem cell therapies against Parkinson's disease
Two independent clinical trials demonstrate the safety of stem cell therapies for Parkinson's disease. The papers, published in Nature, investigate the use of cells derived from human induced pluripotent stem cells and human embryonic stem cells, respectively. Parkinson's disease is characterised by the progressive loss of dopamine-producing neurons. Cell therapy, which replenishes dopamine-producing neurons in the brain, could provide a treatment with fewer adverse effects than current treatments. However, further research is needed to test the efficacy and benefits of these new therapies.